AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and End
AbbVie presented Phase 3 AFFIRM study results showing SKYRIZI® (risankizumab-rzaa) achieved higher rates of endoscopic remission and ulcer-free endoscopy in Crohn's disease patients compared to placebo. The data support FDA approval for subcutaneous induction dosing. SKYRIZI is already approved for other immune-mediated diseases.
How this was made
The 30-second read
Why it matters
New week 12 and week 24 endoscopic remission and ulcer-free endoscopy results versus placebo strengthen the clinical narrative for regulatory submission and potential label expansion.
Market read
Traders may reassess regulatory upside for AbbVie’s Crohn’s subcutaneous induction strategy based on improved endoscopic endpoints at weeks 12 and 24.
What to watch
The article does not provide full safety comparisons beyond “consistent with known profile,” nor does it quantify effect sizes for all co-primary clinical endpoints in this excerpt, leaving some uncertainty around overall benefit-risk.
Background
AbbVie is evaluating a subcutaneous induction dosing regimen for SKYRIZI (risankizumab-rzaa) in adults with moderately to severely active Crohn’s disease in the Phase 3 AFFIRM study.
Ticker impact
AbbVie announced new Phase 3 AFFIRM results for subcutaneous SKYRIZI in Crohn's, including higher week 24 endoscopic remission and ulcer-free endoscopy versus placebo.
Likely upward bias as traders price improved probability of approval and stronger differentiation versus placebo on endoscopic endpoints.
The article discloses new endoscopic remission and ulcer-free endoscopy rates at weeks 12 and 24, plus stated intent to seek FDA approval for a subcutaneous induction dosing regimen.
Market effects
Reinforces IL-23 inhibitor competitive positioning in Crohn’s by emphasizing deeper endoscopic outcomes with a patient-administered subcutaneous regimen.
US-focused read-through via FDA review expectations for AbbVie’s Crohn’s dosing strategy.
EMA review is also referenced, which can broaden the perceived regulatory pathway beyond the US.
Counterpoint
Endoscopic improvements may not translate into durable clinical outcomes or label expansion if regulators focus on broader endpoints beyond endoscopy.
Key entities
- companyAbbVie
Sponsor of the Phase 3 AFFIRM study and presenter of new subcutaneous SKYRIZI Crohn’s endoscopic outcomes.
- drugSKYRIZI (risankizumab-rzaa)
IL-23 inhibitor evaluated for subcutaneous induction in Crohn’s disease.
- clinical_trialAFFIRM
Phase 3 randomized, placebo-controlled, double-blind study assessing subcutaneous risankizumab-rzaa induction in Crohn’s.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory body referenced for an application seeking approval of the subcutaneous induction dosing regimen.
